Yellow fever vaccine
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Yellow fever vaccine
- yf vax
- Yf-vax
- flavivirus yellow fever virus 17d 204 whole
- FLAVIVIRUS YELLOW FEVER VIRUS 17D-204 WHOLE
- stamaril
- Stamaril
- STAMARIL
- Stamaril (live attenuated yellow fever vaccine)
- Stamaril®
- STAMARIL®
- Stamaril™
- yellow fever live attenuated
- Yellow fever vaccination (STAMARIL)
- yellow fever vaccine
- Yellow fever vaccine
- Yellow Fever vaccine
- Yellow Fever Vaccine
- Yellow Fever vaccine (17D)
- Yellow fever vaccine (produced on serum-free Vero cells)
- Yellow Fever Vaccine (Stamaril)
- Yellow fever Vaccine (WHO prequalified)
- yellow fever vaccine (YFV)
- yellow fever virus strain 17d 204
- Yellow fever virus strain 17d-204
- Yellow fever, live attenuated
- ATC classification codes
- J07BL01
Sources for recorded values
- ChEMBL ID
- CHEMBL2108816
- RxNorm IDs (RxCUI)
- 804187
- First in class
- No
- Orphan designation
- No
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition
- Salmonella Food Poisoning
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007475
- Subject identifier
- D012478
- Condition
- Fever
- Highest recorded phase
- 3
- Condition identifier
- HP:0001945
- Subject identifier
- D005334
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007444
- Condition identifier
- HP_0001945
- Highest recorded phase
- 3
- Event
- abortion
- Reports
- 3
- Reporting signal score
- 15.7143
- Event
- chills
- Reports
- 6
- Reporting signal score
- 15.6739
- Event
- chronic eosinophilic leukaemia
- Reports
- 1
- Reporting signal score
- 9.17891
- Event
- contraindication to vaccination
- Reports
- 2
- Reporting signal score
- 14.8599
- Event
- cough
- Reports
- 6
- Reporting signal score
- 11.4652
- Event
- decreased appetite
- Reports
- 6
- Reporting signal score
- 13.1522
- Event
- dehydration
- Reports
- 6
- Reporting signal score
- 14.2963
- Event
- disturbance in attention
- Reports
- 6
- Reporting signal score
- 21.7326
- Event
- dyslexia
- Reports
- 6
- Reporting signal score
- 46.7639
- Event
- impaired work ability
- Reports
- 6
- Reporting signal score
- 28.8846
- Event
- malaise
- Reports
- 6
- Reporting signal score
- 9.08195
- Event
- memory impairment
- Reports
- 7
- Reporting signal score
- 21.5635
- Event
- metastatic squamous cell carcinoma
- Reports
- 2
- Reporting signal score
- 13.474
- Event
- night sweats
- Reports
- 6
- Reporting signal score
- 24.2915
- Event
- oral hyperaesthesia
- Reports
- 1
- Reporting signal score
- 8.92761
- Event
- paraesthesia
- Reports
- 5
- Reporting signal score
- 11.0531
- Event
- pneumonitis aspiration
- Reports
- 1
- Reporting signal score
- 8.72695
- Event
- pyrexia
- Reports
- 8
- Reporting signal score
- 14.0702
- Event
- rash
- Reports
- 6
- Reporting signal score
- 8.06541
- Event
- reading disorder
- Reports
- 2
- Reporting signal score
- 11.875
- Event
- sleep disorder
- Reports
- 6
- Reporting signal score
- 20.3265
- Event
- sneezing
- Reports
- 4
- Reporting signal score
- 16.2987
- Event
- transaminases increased
- Reports
- 6
- Reporting signal score
- 21.7051
- Event
- vaccination error
- Reports
- 1
- Reporting signal score
- 8.4858
- Event
- vertigo
- Reports
- 3
- Reporting signal score
- 7.4176
And 6 more, listed on the interactive page.
- NCT00723489
- NCT00995865
- NCT02743455
- NCT03116802
- NCT04269265
- NCT04942210
- NCT05011123
- NCT05332197
- NCT05421611
- NCT05447377
- NCT01345240
- NCT02699099
- NCT05468606
- NCT06213506
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (48)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
- Antibiotics and Vaccine Immune Responses Study
- Booster Vaccine for Yellow Fever
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
- Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination
- Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
- Human Immune Responses to Yellow Fever Vaccination
- Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali
- Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
- Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
- Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination
- Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)
- Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals
In development for (4)
- Atopic eczema Phase 1
- Malaria Phase 3
- Plasmodium falciparum malaria Early phase 1
- Salmonella gastroenteritis Phase 2